AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15383180 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily (TB group: 22 patients)
Number of subjects: 44
Study 15383180 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination of latanoprost 0.005%/timolol 0.5% once daily (LT group: 22 patients)
Number of subjects: 44
Study 12539556 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaokuiling prescription (XKL)
Number of subjects: 0
Study 9397242 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐21268 (100 mg)
Number of subjects: 40
Study 9397242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9397242 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐21268
Number of subjects: 40
Study 7968562 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of drooling in clients identified as drooling
Number of subjects: 2
Study 7968562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling of drooling amounts in 2 clients identified as drooling
Number of subjects: 2
Study 2822298 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine (alpha‐1 adrenoceptor agonist)
Number of subjects: 6
Study 2822298 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine (alpha‐1 adrenoceptor antagonist)
Number of subjects: 6
Study 2822298 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 6
Study 2822298 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 6
Study 29557858 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved caregiver depressive symptoms
Number of subjects: 156
Study 29557858 — intervention group
Group type: COMPARATOR
Intervention: No significant changes in caregiver depressive symptoms
Number of subjects: 156
Study 29557858 — intervention group
Group type: COMPARATOR
Intervention: Worsening caregiver depressive symptoms
Number of subjects: 156
Study 27618516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mung bean bag (MB) exercise group
Number of subjects: 39
Study 27618516 — intervention group
Group type: EXPERIMENTAL
Intervention: Firm surface (FS) exercise group
Number of subjects: 39
Study 27618516 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 25184981 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetrics mannequin
Number of subjects: 110
Study 25184981 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthing pelvis model
Number of subjects: 110
Study 25184981 — intervention group
Group type: COMPARATOR
Intervention: Both simulators (combined results)
Number of subjects: 110
Study 23603346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine antagonist (haloperidol)
Number of subjects: 49
Study 23603346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (levodopa)
Number of subjects: 49
Study 23603346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 19732095 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (300 mg)
Number of subjects: 15
Study 19732095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg)
Number of subjects: 15
Study 18200024 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled racemic epinephrine
Number of subjects: 20
Study 18200024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15994288 — intervention group
Group type: EXPERIMENTAL
Intervention: PSC-833
Number of subjects: 419
Study 15994288 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine
Number of subjects: 419
Study 12499338 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic meal with 50 g pork
Number of subjects: 45
Study 12499338 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic meal with 75 g pork
Number of subjects: 45
Study 12499338 — intervention group
Group type: COMPARATOR
Intervention: Basic meal with 25 g pork
Number of subjects: 45
Study 12499338 — intervention group
Group type: COMPARATOR
Intervention: Basic meal (control)
Number of subjects: 45
Study 11096386 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal cooling with IPL treatment
Number of subjects: 25
Study 11096386 — intervention group
Group type: COMPARATOR
Intervention: Non-cooled IPL treatment
Number of subjects: 25
Study 11096386 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover treatment with cooling
Number of subjects: 25
Study 8558209 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 5 micrograms/kg on days 1 to 12 and GM‐CSF at 0.5, 1, or 5 micrograms/kg on days 7 to 12
Number of subjects: 5
Study 8558209 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF 5 micrograms/kg on days 1 to 12 and G‐CSF 5 micrograms/kg on days 7 to 12
Number of subjects: 5
Study 8558209 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF added to patients already receiving GM‐CSF (cohort 4)
Number of subjects: 5
Study 8558209 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF added to patients already receiving G‐CSF
Number of subjects: 5
Study 8558209 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline apheresis CFU‐GM content
Number of subjects: 5
Study 1911129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 105
Study 1911129 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 105
Study 7065884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagotomy and pyloroplasty
Number of subjects: 344
Study 7065884 — intervention group
Group type: COMPARATOR
Intervention: Vagotomy and hemigastrectomy
Number of subjects: 344
Study 31996613 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (280 mg)
Number of subjects: 10
Study 31996613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee)
Number of subjects: 10
Study 31030870 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I (Cognitive Bias Modification for Interpretation)
Number of subjects: 127
Study 31030870 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM-I
Number of subjects: 127
Study 31030870 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral WSAP task or treatment as usual)
Number of subjects: 127
Study 28933711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip joint angle at 145° (hip145)
Number of subjects: 28
Study 28933711 — intervention group
Group type: COMPARATOR
Intervention: Hip joint angle at 175° (hip175)
Number of subjects: 28
Study 25673979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mécano‐Stimulation™
Number of subjects: 30
Study 24717956 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable gelatin dressing impregnated with triamcinolone
Number of subjects: 60
Study 24717956 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 22866291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 mm dental implants with a novel nanostructured calcium‐incorporated titanium surface
Number of subjects: 80
Study 22866291 — intervention group
Group type: COMPARATOR
Intervention: at least 5 × 10 mm‐long implants in augmented bone
Number of subjects: 80
Study 19682360 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine (DAM)
Number of subjects: 62
Study 19682360 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (MMT)
Number of subjects: 62
Study 17440010 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 44
Study 17440010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15311110 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8206
Study 15311110 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8206
Study 15894527 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 19
Study 15894527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10618798 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assessment methods (thresholds, quality and variability relationship, sensitivity analysis, quality scores)
Number of subjects: 0
Study 10618798 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidated Standards of Reporting Trials (CONSORT) initiative
Number of subjects: 0
Study 8740604 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized electrical tooth stimulation at 6 different levels of intensity
Number of subjects: 0
Study 8740604 — intervention group
Group type: COMPARATOR
Intervention: Constant intensity stimulation
Number of subjects: 0
Study 8740604 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized stimulation with a 1-sec interstimulus interval (ISI)
Number of subjects: 0
Study 8740604 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized stimulation with a prolonged ISI
Number of subjects: 0
Study 8740604 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized stimulation with a 3-sec ISI
Number of subjects: 0
Study 1890501 — intervention group
Group type: EXPERIMENTAL
Intervention: High craving group (n=39)
Number of subjects: 179
Study 1890501 — intervention group
Group type: COMPARATOR
Intervention: Low craving group (n=115)
Number of subjects: 179
Study 1890501 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high withdrawal symptom severity group (n=151)
Number of subjects: 179
Study 1890501 — intervention group
Group type: COMPARATOR
Intervention: Low withdrawal symptom severity group (n=27)
Number of subjects: 179
Study 6804162 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol 50 micrograms + Norethisterone 1mg (MES 50 + NET 1)
Number of subjects: 518
Study 6804162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 micrograms + Levonorgestrel 150 micrograms (EE 30 + LNG 150)
Number of subjects: 518
Study 6804162 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone 350 micrograms (NET 350)
Number of subjects: 518
Study 6804162 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 30 micrograms (LNG 30)
Number of subjects: 518
Study 30951166 — intervention group
Group type: EXPERIMENTAL
Intervention: PrabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Number of subjects: 540
Study 30951166 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U, 0.1 mL injected into each of 5 glabellar sites)
Number of subjects: 540
Study 30951166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 31390743 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in classroom behaviour management (mean 11.5 hours over 8 months)
Number of subjects: 220
Study 31390743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 220
Study 29630796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing group (n=48, 27 AM; 21 RC)
Number of subjects: 34
Study 29630796 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=89, 59 AM; 30 RC)
Number of subjects: 34
Study 27244762 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 1-2 of the cycle (Group A)
Number of subjects: 181
Study 27244762 — intervention group
Group type: COMPARATOR
Intervention: GnRH‐a (Triptorelin) subcutaneous daily injections starting on day 20-22 of the previous cycle (Group B)
Number of subjects: 181
Study 27244762 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a (Triptorelin) subcutaneous daily injections (both groups)
Number of subjects: 181
Study 24928295 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 2499
Study 24928295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study 22343005 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manipulative intervention
Number of subjects: 56
Study 22343005 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 56
Study 20052352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 IU/day) in group S
Number of subjects: 3
Study 20052352 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed (group B) and breast-fed with vitamin D supplementation (group S)
Number of subjects: 3
Study 20052352 — intervention group
Group type: COMPARATOR
Intervention: Total intake of vitamin D in groups A, S, and B
Number of subjects: 3
Study 20052352 — intervention group
Group type: COMPARATOR
Intervention: Total intake of Ca and P in groups A, B, and S
Number of subjects: 3
Study 17610534 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg qd for 3 days, then 80 mg qd for 7 days)
Number of subjects: 24
Study 17610534 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24
Study 16244051 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score analysis
Number of subjects: 0
Study 16244051 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification tree analysis and bagging for classification trees
Number of subjects: 0
Study 12366619 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 295
Study 12366619 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 295
Study 10448545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylic acid (L-ASA) 1.8 g i.v. (1 g acetylsalicylic acid)
Number of subjects: 278
Study 10448545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 278
Study 10448545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 7576743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 139
Study 7576743 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 139
Study 30632837 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus chemotherapy (G + chemo)
Number of subjects: 0
Study 30632837 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus chemotherapy (R + chemo)
Number of subjects: 0
Study 30167783 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBNB proximal approach (group P)
Number of subjects: 70
Study 30167783 — intervention group
Group type: COMPARATOR
Intervention: ICBNB distal approach (group D)
Number of subjects: 70
Study 27339661 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined AUDADIS‐IV (n=166)
Number of subjects: 497
Study 27339661 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit withdrawal stem (n=167)
Number of subjects: 497
Study 27339661 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit hangover stem (n=164)
Number of subjects: 497
Study 23334749 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Well intervention (lifestyle intervention to prevent weight gain)
Number of subjects: 383
Study 22707132 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVFX) 250 mg orally
Number of subjects: 120
Study 22707132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 120
Study 22707132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19166694 — intervention group
Group type: COMPARATOR
Intervention: Nicotinic acid (1,500 mg/day) plus placebo
Number of subjects: 0
Study 19166694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1,500 mg/day) plus gemfibrozil (1,200 mg/day)
Number of subjects: 0
Study 17151802 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (high-dose intravenous proton pump inhibitor)
Number of subjects: 249
Study 17151802 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (high-dose intravenous proton pump inhibitor) + Misoprostol (600 microg/day)
Number of subjects: 249
Study 15057738 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA (8 mg/kg biweekly)
Number of subjects: 36
Study 15057738 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA (every 4 weeks)
Number of subjects: 36
Study 15057738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11442185 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical verapamil (0.25%)
Number of subjects: 56
Study 11442185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine (0.5 mg/day)
Number of subjects: 62
Study 9758438 — intervention group
Group type: COMPARATOR
Intervention: Levo-thyroxine (T4) (0.125 mg/day)
Number of subjects: 62
Study 9758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients who developed autoimmunity
Number of subjects: 62
Study 7798975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 70
Study 7798975 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography
Number of subjects: 70
Study 7798975 — intervention group
Group type: COMPARATOR
Intervention: Digital Subtraction Angiography
Number of subjects: 70
Study 3044833 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus Poly(A).Poly(U)
Number of subjects: 300
Study 3044833 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 300
Study 31161436 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant and palonosetron (NEPA)
Number of subjects: 828
Study 31161436 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant plus granisetron (APR + GRAN)
Number of subjects: 828
Study 29256091 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 148
Study 29256091 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 148
Study 27878630 — intervention group
Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels measured at admission (122.44 ± 41.01 ng/ml)
Number of subjects: 50
Study 27878630 — intervention group
Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels measured after treatment (71.38 ± 49.68 ng/ml)
Number of subjects: 50
Study 27878630 — intervention group
Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels at admission (cutoff point of 45 ng/ml)
Number of subjects: 50
Study 27878630 — intervention group
Group type: EXPERIMENTAL
Intervention: cMyBP‐C plasma levels at admission (cutoff point of 152 ng/ml)
Number of subjects: 50
Study 27878630 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment
Number of subjects: 50
Study 26142168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and occupational therapy (Group B, n=30)
Number of subjects: 61
Study 26142168 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only (Group A, n=31)
Number of subjects: 61
Study 23139265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 40
Study 23139265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21992747 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced ketosis
Number of subjects: 0
Study 21992747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17874244 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Surgery (CAS)
Number of subjects: 73
Study 17874244 — intervention group
Group type: COMPARATOR
Intervention: Standard single incision technique (without CAS)
Number of subjects: 73
Study 16644438 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3D contrast echocardiography
Number of subjects: 14
Study 16644438 — intervention group
Group type: COMPARATOR
Intervention: Noncontrast 3D imaging
Number of subjects: 14
Study 12551742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin tetrapeptide (CCK‐4) infusion
Number of subjects: 24
Study 12551742 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study 11015511 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral iron supplementation (EI) of 2 to 6 mg/kg/day
Number of subjects: 133
Study 11015511 — intervention group
Group type: COMPARATOR
Intervention: Late enteral iron supplementation (LI)
Number of subjects: 133
Study 8779128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1500 micrograms
Number of subjects: 12
Study 8779128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 2000 micrograms
Number of subjects: 12
Study 8779128 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 2000 micrograms
Number of subjects: 12
Study 8779128 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms
Number of subjects: 12
Study 8779128 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 12
Study 1355153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 198
Study 1355153 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 198
Study 1355153 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA typed with a donor
Number of subjects: 198
Study 6354151 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin
Number of subjects: 0
Study 6354151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) high‐dosage cyclophosphamide
Number of subjects: 0
Study 6354151 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 0
Study 30345574 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIP + IMP
Number of subjects: 93
Study 30345574 — intervention group
Group type: COMPARATOR
Intervention: SBIP
Number of subjects: 93
Study 28718073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes (Oxabact™ OC3)
Number of subjects: 36
Study 28718073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26932324 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 0
Study 26932324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation treatment
Number of subjects: 0
Study 26932324 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and stage of change post intervention
Number of subjects: 0
Study 24152824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 0
Study 24152824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22575719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention focused on improving quality-of-life outcomes for co-occurring cancer and depression
Number of subjects: 24